Additional Information
| Product Name: | ABT-263 (Navitoclax) |
|---|---|
| Also Known As: | 4-[4-[[2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[4-[[(1R)-3-(4-morpholinyl)-1-[(phenylthio)methyl]propyl]amino]-3-[(trifluoromethyl)sulfonyl]phenyl]sulfonyl]-benzamide |
| Catalog No.: | F7141 |
| Size: | 25 mg |
| CAS: | 923564-51-6 |
| Formula: | C47H55ClF3O6S3 |
| Molecular Weight: | 974.61 g/mol |
| Form: | Lyophilized powder |
| Quality Assurance: | >98% by HPLC and NMR |
| Source: | Synthetic |
| Storage: | Eligible for room temperature shipping. Store at -20°C upon receiving; protect from air and ligh |
| PDF Data Sheet: | Download PDF datasheet， MSDS |
| Image(s): | N/A |
| Shipping Method: | Room temperature shipping |
| References: | Tse C, et al. (2008) Cancer Res. 68(9), 3421-3428. |
Details
ABT-263 (Navitoclax) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki ~ 0.5 nM, 1 nM and 1 nM in cell-free assays. ABT-263 blocks the Bcl-2/Bcl-xL interactions, thereby promoting apoptosis.
Solubility:
> 20 mg/ml in DMSO
Working Condition:
1 μM in cell culture assay
Solubility:
> 20 mg/ml in DMSO
Working Condition:
1 μM in cell culture assay
